{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:21:43Z","timestamp":1782512503036,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/nrclinonc.2010.68","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T09:31:53Z","timestamp":1275471113000},"page":"303-304","source":"Crossref","is-referenced-by-count":2,"title":["Imatinib\u2014should we have more of a good thing?"],"prefix":"10.1038","volume":"7","author":[{"given":"Jane F.","family":"Apperley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrclinonc201068_CR1","unstructured":"US Department of Health and Human Services http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2001\/21335ltr.pdf (2001)."},{"key":"BFnrclinonc201068_CR2","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah, N. P. et al. Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204\u20133212 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201068_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201068_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes, J. E. et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28, 424\u2013430 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201068_CR5","doi-asserted-by":"crossref","unstructured":"Marin, D. et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. doi: 10.1200\/JCO.2009.26.3087.","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"BFnrclinonc201068_CR6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal, J. E. et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63, 789\u2013799 (1984).","journal-title":"Blood"},{"key":"BFnrclinonc201068_CR7","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani, M. et al. Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113, 4497\u20134504 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201068_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","volume":"107","author":"AS Yong","year":"2006","unstructured":"Yong, A. S., Szydlo, R. M., Goldman, J. M., Apperley, J. F. & Melo, J. V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107, 205\u2013212 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201068_CR9","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich, J. P. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 103, 2794\u20132799 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201068_CR10","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V114.22.4972.4972","volume":"114","author":"G Saglio","year":"2009","unstructured":"Saglio, G. et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial [abstract]. Blood 114, LBA\u20131 (2009).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.68","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:06:04Z","timestamp":1684469164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFnrclinonc201068"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.68","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}